Search results
Results from the WOW.Com Content Network
MDA-19 binds to human CB 2 receptors at K i = 43.3 ± 10.3 nM and human CB 1 receptors at K i = 162.4 ± 7.6 nM and functions as an agonist in human cannabinoid receptors but functions differently in rat cannabinoid receptors binding to rat cannabinoid CB 2 receptors at K i = 16.3 ± 2.1 and CB 1 receptors at K i = 1130 ± 574 nM binding to rat CB 1 receptors 6.9× weaker than human CB 1 ...
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a K i of 1.0 nM at CB 1 and 2.6 nM at CB 2. [6] The 4-methyl functional analog MAM-2201 probably has similar affinities. [original research?] AM-2201 has an EC 50 of 38 nM for human CB 1 receptors, and 58 nM for human CB 2 receptors. [7]
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
JWH-018 is a full agonist of both the CB 1 and CB 2 cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB 1 and 2.94 ± 2.65 nM at CB 2. [6] JWH-018 has an EC 50 of 102 nM for human CB 1 receptors, and 133 nM for human CB 2 receptors. [16]
Arachidonyl-2'-chloroethylamide (ACEA) is a synthetic agonist of the CB 1 (CB1R). ACEA is considered to be a selective cannabinoid agonist as it binds primarily to the CB1R and has low affinity to the CB 2 (CB2R) (K i = 1.4 nM for CB1R; K i = 3100 nM for CB2R).
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the ...
NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018 [1] that is an agonist for the cannabinoid receptors, with K i values of 60.09 nM at CB 1 and 45.298 nM at CB 2 and EC 50 values of 9.481 nM at CB 1 and 1.008 nM at CB 2. [2]
ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards [1]) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. [2] It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB 1 receptor with a binding affinity (K i) of 0.33 nM and an EC 50 ...